- Home
- OKLO vs OCS Comparison
OKLO vs OCS Comparison
Compare OKLO & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKLO
- OCS
- Stock Information
- Founded
- OKLO 2013
- OCS 2003
- Country
- OKLO United States
- OCS Switzerland
- Employees
- OKLO N/A
- OCS N/A
- Industry
- OKLO
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- OKLO
- OCS Health Care
- Exchange
- OKLO NYSE
- OCS Nasdaq
- Market Cap
- OKLO 710.6M
- OCS 706.3M
- IPO Year
- OKLO N/A
- OCS N/A
- Fundamental
- Price
- OKLO $18.00
- OCS $14.14
- Analyst Decision
- OKLO Buy
- OCS Strong Buy
- Analyst Count
- OKLO 2
- OCS 5
- Target Price
- OKLO $10.00
- OCS $29.20
- AVG Volume (30 Days)
- OKLO 25.5M
- OCS 73.4K
- Earning Date
- OKLO 11-14-2024
- OCS 11-07-2024
- Dividend Yield
- OKLO N/A
- OCS N/A
- EPS Growth
- OKLO N/A
- OCS N/A
- EPS
- OKLO N/A
- OCS N/A
- Revenue
- OKLO N/A
- OCS $1,027,571.00
- Revenue This Year
- OKLO N/A
- OCS $4.38
- Revenue Next Year
- OKLO N/A
- OCS $905.09
- P/E Ratio
- OKLO N/A
- OCS N/A
- Revenue Growth
- OKLO N/A
- OCS N/A
- 52 Week Low
- OKLO $5.35
- OCS $9.60
- 52 Week High
- OKLO $28.12
- OCS $18.00
- Technical
- Relative Strength Index (RSI)
- OKLO 46.38
- OCS 37.01
- Support Level
- OKLO $21.79
- OCS $16.44
- Resistance Level
- OKLO $25.65
- OCS $18.00
- Average True Range (ATR)
- OKLO 3.27
- OCS 0.68
- MACD
- OKLO -0.71
- OCS -0.46
- Stochastic Oscillator
- OKLO 6.34
- OCS 3.50
About OKLO OKLO INC
Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.